Biotechnology company Elicera Therapeutics AB (publ) announced on Monday that its drug candidate ELC-100 has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for treating pancreatic neuroendocrine tumours.
ODD supports the development of treatments for rare diseases, with benefits including tax credits for US clinical trials and potential fee waivers for marketing approval. In addition, ODD provides up to seven years of market exclusivity upon approval.
ELC-100 is based on an oncolytic virus and targets neuroendocrine cancer cells selectively. Elicera is currently conducting a Phase I/II trial to determine the maximum tolerated dose (MTD) and assess safety. The company completed patient recruitment for the trial's first part in fall 2024. Final data from this phase is expected in mid-2025.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval